We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.03 | -0.12% | 25.36 | 237,738 | 14:25:07 |
From Apr 2022 to Apr 2024
By Colin Kellaher
Voyager Therapeutics Inc. on Tuesday said Pfizer Inc. exercised one of two options to license a novel capsid generated from its Tracer capsid discovery platform, letting the second option lapse.
The Cambridge, Mass., gene-therapy company said Pfizer's exercise of the option targeting an undisclosed rare neurologic disease triggers a $10 million payment from the New York drugmaker.
Last October, Voyager said it had inked an agreement with Pfizer for the two options, targeting central-nervous-system and cardiovascular diseases. Voyager received $30 million upfront and was eligible for up to $20 million in exercise fees, as well as up to $580 million in potential milestone payment.
Voyager said it remains eligible for up to $290 million in milestone payments related to the neurologic disease, while all rights to the capsid for a cardiovascular disease target revert to the company.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 04, 2022 07:44 ET (11:44 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
